曳野圭子

Keiko Hikino

基本情報

所属: 東京慈恵会医科大学臨床薬理学講座講師
理化学研究所生命医科学研究センターファーマコゲノミクス研究チーム客員研究員
藤田医科大学研究推進本部ゲノミクス医学センター統計応用遺伝医学講座客員講師
静岡県立総合病院リサーチサポートセンター客員研究員

学位: 学士（医学）(島根大学)
医学博士(2020年4月横浜市立大学)

研究者番号: 10789580
ORCID ID: https://orcid.org/0000-0002-4852-2401
J-GLOBAL ID: 201901008820546985
researchmap会員ID: B000373995

研究キーワード

研究分野

経歴

2026年4月 - 現在

東京慈恵会医科大学, 臨床薬理学講座講師
2026年4月 - 現在

理化学研究所生命医科学研究センター, ファーマコゲノミクス研究チーム客員研究員
2026年4月 - 現在

藤田医科大学, 研究推進本部ゲノミクス医学センター, 統計応用遺伝医学講座客員講師
2026年4月 - 現在

静岡県立総合病院, リサーチサポートセンター客員研究員
2024年4月 - 2026年3月

理化学研究所生命医科学研究センターファーマコゲノミクス研究チーム研究員

もっとみる

委員歴

2025年1月 - 現在

日本臨床薬理学会国際交流・リエゾン委員会委員
2025年1月 - 現在

Editorial Board of the Journal of International Medical Research

受賞

2026年5月

ESHG 2026 Annual Meeting Travel Award at the Japanese Society of Human Genetics 2026 Annual Meeting
2026年3月

Performance Incentive (FY2025), Integrative Medical Sciences, RIKEN
2025年11月

日本医師会医学研究奨励賞
2025年3月

Performance Incentive (FY2024), Integrative Medical Sciences, RIKEN
2023年3月

Performance Incentive (FY2022), Integrative Medical Sciences, RIKEN

もっとみる

論文

Decomposing population differences in type 2 diabetes through a high-resolution GWAS of ~600,000 individuals with East Asian ancestry

Kohei Saito, Hsing-Fang Lu, Tatsuhide Inoue, Takeshi Usui, Toshihiro Shirai, Tatsuo Ogawa, Rieko Kosugi, Chika Kyo, Keiko Hikino, Yun Li, Momoko Horikoshi, Hiroshi Itoh, Kaori Hayashi, Toshio Shimada, Koichi Ozaki, Issei Tanaka, Wen-Ling Liao, Yen-Ting Chang, Ting-Yuan Liu, Fuu-Jen Tsai, Chikashi Terao

Communications Biology 2026年9月30日査読有り
Multi-population GWAS meta-analysis identifies bladder cancer susceptibility loci and highlights genetic regulation of smoking-related risk

Ludmila Prokunina-Olsson, Oscar Florez-Vargas, Michael G. Levin, Diptavo Dutta, Charles E. Breeze, Lauren M. Hurwitz, Wusheng Yan, Philippe Lamy, Brenen W. Papenberg, Kevin Wang, Chia-Han Lee, Roger L. Milne, Jian Gu, Caroline Y. Um, Vijai Joseph, Helena Furberg, Florence Le Calvez-Kelm, Adriana Lori, Parichoy Pal Choudhury, Nina Afshar, Manolis Kogevinas, Kenneth Offit, Sita H. Vermeulen, Evangelina López de Maturana, Demetrius Albanes, Mark P. Purdue, Victoria K. Cortessis, Margaret R. Karagas, Charles Kooperberg, Marc Bjurlin, Deborah A. Tadesse, Steven C. Moore, Wen-Yi Huang, Christopher A. Haiman, Mariana C. Stern, A. Heather Eliassen, Lorelei A. Mucci, Katja K. Aben, Tessel E. Galesloot, Tatjana Simic, Dejan Dragicevic, Arndt Hartmann, Veronika Weyerer, Danijel Sikic, Gregers G. Hermann, Karin Mogensen, Marcus Horstmann, Marc-Oliver Grimm, Roman Nawroth, Tobias Maurer, Ellen C. Zwarthoff, Kim E. M. van Kessel, Lars Dyrskjøt, Torben Ørntoft, Sia Viborg Lindskrog, Frederik Prip, Jørgen Bjerggaard Jensen, Ulrika Segersten, Per-Uno Malmström, Astrid C. Petersen, Anurag Verma, Soichiro Yoshino, Keiko Hikino, Chikashi Terao, Thorunn Rafnar, Koichi Matsuda, Taro Shuin, Montserrat Garcia-Closas, Francisco X. Real, Lambertus A. Kiemeney, Stephen J. Chanock, Núria Malats, Debra T. Silverman, Lars Dyrskjot, Nathaniel Rothman, Scott M. Damrauer, Stella Koutros, Jeffrey S. Damrauer

Nature Communications 2026年8月8日査読有り
Associations between mosaic loss and schizophrenia or bipolar disorder of young age

Shunsuke Uchiyama, Takeo Saito, Xiaoxi Liu, Yuki Ishikawa, Keiko Hikino, Masashi Ikeda, Giulio Genovese, Nakao Iwata, Chikashi Terao

Molecular Psychiatry 2026年5月査読有り
Multi-ancestry genome-wide association analyses of refractive error augment genetic discovery and polygenic prediction

Fei-Fei Cheng, Xiaoxi Liu, Hao Mi, Lizhong Wang, Ruilei Ma, Yazhou Guo, Julia Sidorenko, Chen Jiang, Tania Islam, Akira Meguro, Keiko Hikino, Yuki Ishikawa, Senwei Tang, Teng Li, Ruoyan Chen, Likun Wang, Reedik Mägi, Andres Metspalu, Estonian Biobank Research Team, Lili Milani, Tõnu Esko, Mari Nelis, Georgi Hudjashov, 23andMe Research Team, Adam Auton, Alan Kwong, Anjali J. Shastri, Barry Hicks, Catherine H. Weldon, David A. Hinds, Emily DelloRusso, Emily M. Rios, Joyce Y. Tung, Kahsaia de Brito, Katelyn Kukar Bond, Keng-Han Lin, Matthew H. McIntyre, Matthew J. Kmiecik, Qiaojuan Jane Su, Robert K. Bell, Sayantan Das, Shubham Saini, Stella Aslibekyan, Vinh Tran, Wanwan Xu, Alisa P. Lehman, Noura S. Abul-Husn, R. Ryanne Wu, Rebecca M. K. Berns, Ruth I. Tennen, Stacey B. Detweiler

Nature Genetics 2026年4月20日査読有り
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT3 Receptor Antagonists: 2026 Update.

Claire Moore, Melissa S Bourque, Andreas Halman, José A G Agúndez, Cynthia A Prows, Keiko Hikino, Matthias Schwab, Carolyn J Oxencis, Dharmisha Chauhan, Meta H M Diekstra, Susie E Long, Gillian C Bell, Andrea Gaedigk, Michelle Whirl-Carrillo, Teri E Klein, Kelly E Caudle, Rachel Conyers

Clinical pharmacology and therapeutics 2026年4月14日査読有り

5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting. Most of the 5-HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent of CYP2D6 involvement varies. CYP2D6 genetic variation can influence the metabolism of these medications, particularly ondansetron and tropisetron, thereby affecting drug efficacy. This guideline is an update to the 2016 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron and includes updated information on CYP2D6 genetic testing and evidence tables. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5-HT3 receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457).